Milvexian targets the activated, or clot-initiating, form of factor XI, called factor XIa. Harvard’s Gibson is leading one of the trials. Also in the mix is Anthos Therapeutics, a startup ...

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.